The biotech sector was on a bumpy ride over the week as shares of Spectrum surged on positive data from a phase II study, while that of Incyte plunged on the failure of melanoma study. In an effort to bolster its presence in the gene …
10 stocks we like better than Incyte When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* David and …
SmarTrend identified a Downtrend for Incyte Corp (NASDAQ:INCY) on March 19th, 2018 at $87.42. In approximately 3 months, Incyte Corp has returned 22.17% as of today's recent price of $68.04. In the past 52 weeks, Incyte Corp share …
Incyte has gapped open sharply lower this morning and is now down 18.37 at $64.69 on strong volume. The stock has tumbled to a new low for the year.
The stock's 50-day moving average of $162.38 is lower than its 200-day moving average of $171.08. Shares of Allergan have fallen roughly 1.62 percent in the past month and are down 4.08 percent year-to-date. On Tuesday, shares of Incyte …
Incyte Corp. (NASDAQ: INCY) said on Friday that its experimental drug epacadostat failed to improve the efficiency of Merck & Co’s (NYSE: MRK) Keytruda immunotherapy treatment when the two were used together by newly diagnosed …
Incyte Corp. (NASDAQ: INCY) said on Friday that its experimental drug epacadostat failed to improve the efficiency of Merck & Co’s (NYSE: MRK) Keytruda immunotherapy treatment when the two were used together by newly diagnosed …
This suggests that analysts have very recently bumped up their estimates for INCY, giving the stock a Zacks Earnings ESP of +20.72% heading into earnings season. A positive reading for the Zacks Earnings ESP has proven to be very …
This suggests that analysts have very recently bumped up their estimates for INCY, giving the stock a Zacks Earnings ESP of +40.11% heading into earnings season. Why is this Important? A positive reading for the Zacks Earnings ESP …
This suggests that analysts have very recently bumped up their estimates for INCY, giving the stock a Zacks Earnings ESP of +40.11% heading into earnings season. Why is this Important? A positive reading for the Zacks Earnings ESP …